Loading stock data…
$4.20-0.04 (-0.94%)
ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases.
ImageneBio, Inc. in the Healthcare sector is trading at $4.20 with a market capitalization of $57M. Wall Street consensus targets $18.00 (3 analysts), implying a +328.6% move over the next 12 months. The stock is currently near its 52-week low of $3.90, remaining 27.5% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 23 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$11.78M↑ | -$12.08M↓ | -$8.50M↑ | -$26.59M↓ | -$7.36M |
| Net Income | -$10.18M↑ | -$10.62M↓ | -$6.91M↑ | -$24.78M↓ | -$7.58M |
ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that...